A Phase 3, Randomized, Double-blind, Comparator- and Placebo-controlled Study to Evaluate the Safety and Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy
TLC Biopharmaceuticals, Inc.
Summary
This is a Phase 3, randomized, double-blind, comparator- and placebo-controlled study to evaluate analgesic efficacy and safety of TLC590 via local infiltration in adult subjects following bunionectomy.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Able and willing to provide written informed consent. 2. Male or female aged 18 years or older (inclusive). 3. Scheduled to undergo a primary unilateral, transpositional first metatarsal bunionectomy with osteotomy and internal fixation under regional anesthesia. 4. ASA Physical Status Classification of 1 or 2. 5. Male subjects must be either biologically or surgically sterile or commit to the use of a reliable method of birth control (must agree to use double-barrier contraception in the event of sexual activity) or be practicing abstinence. 6. Female subjects are elig…
Interventions
- DrugTLC590
TLC590 (Ropivacaine Extended-Release Injectable Suspension)
- DrugLiposomal Bupivacaine
Bupivacaine Liposome Injectable Suspension
- DrugSaline Placebo
Normal Saline 0.9%
Locations (4)
- Clinical Pharmacology of MiamiMiami, Florida
- First Surgical HospitalBellaire, Texas
- Memorial Hermann VillageHouston, Texas
- Endeavor Clinical TrialsSan Antonio, Texas